Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ALS
ALS
Amylyx counters Wall Street noise, cites demand for ALS drug
Medical Marketing and Media
Wed, 02/15/23 - 10:39 am
Amylyx Pharmaceuticals
Relyvrio
ALS
Cigna restricts coverage of new ALS drug, deepening fears about access
BioPharma Dive
Wed, 02/8/23 - 10:48 am
Amylyx Pharmaceuticals
ALS
Relyvrio
insurers
Cigna
Amylyx completes subject enrollment in ALS therapy trial
Clinical Trials Arena
Fri, 02/3/23 - 10:33 am
Amylyx
clinical trials
AMX0035
ALS
UniQure nabs another gene therapy for ALS
BioPharma Dive
Tue, 01/31/23 - 12:34 pm
UniQuire
Apic Bio
ALS
gene therapy
AMT-162
Biogen/ Ionis ALS therapy set for March FDA AdCom meeting
Seeking Alpha
Mon, 01/23/23 - 11:12 am
Biogen
Ionis Pharmaceuticals
FDA
ALS
tofersen
For ALS patients, doctors, a new medicine reignites concerns about healthcare access
BioPharma Dive
Thu, 12/15/22 - 10:58 am
Amylyx
Relyvrio
ALS
patients
physicians
Biogen's ALS Drug Tofersen Filing Accepted in Europe
Zacks.com
Tue, 12/6/22 - 10:48 am
Biogen
ALS
EMA
Europe
tofersen
BrainStorm Vows to Push for Adcomm Meeting on NurOwn in ALS
BioSpace
Mon, 11/14/22 - 10:53 am
BrainStorm Cell Therapeutics
NurOwn
ALS
FDA
Not once, but twice: BrainStorm shares tumble as FDA again knocks back ALS drug
Fierce Biotech
Thu, 11/10/22 - 10:32 am
BrainStorm Cell Therapeutics
ALS
FDA
NurOwn
NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson's, ALS
BioSpace
Thu, 11/10/22 - 10:25 am
NRG Therapeutics
funding
Parkinson's Disease
ALS
Verge Genomics and Stealth Bio Advance Novel Therapeutics in ALS
BioSpace
Wed, 11/2/22 - 10:05 am
ALS
Verge Genomics
Stealth BioTherapeutics
clinical trials
VRG50635
SBT-272
Biogen's Q3 revenue declines 10% as focus shifts to new Alzheimer's and ALS drug candidates
Endpoints
Tue, 10/25/22 - 11:05 am
Biogen
earnings
Alzheimer's disease
ALS
tofersen
lecanemab
Biogen's ALS ambitions on pause as FDA delays approval decision by 3 months
Fierce Biotech
Mon, 10/17/22 - 10:53 am
Biogen
tofersen
FDA
ALS
Days after Relyvrio’s FDA approval, Amylyx announces public offering to fund effort
Medical Marketing and Media
Wed, 10/5/22 - 07:13 pm
Amylyx Pharmaceuticals
ALS
Relyvrio
stock offering
ALS drug's approval draws cheers from patients, questions from skeptics
NPR
Sun, 10/2/22 - 07:45 pm
ALS
FDA
Amylyx Pharmaceuticals
drug pricing
Relyvrio
FDA approves ALS drug from Amylyx, giving patients a much-needed treatment option
Stat
Thu, 09/29/22 - 07:44 pm
Amylyx Pharmaceuticals
ALS
Relyvrio
FDA
Biohaven's ALS drug fails to meet study goals
Yahoo/Reuters
Thu, 09/29/22 - 10:07 am
Biohaven
ALS
clinical trials
troriluzole
Biogen bolsters case for ALS drug under FDA review with new published data
MedCity News
Fri, 09/23/22 - 10:36 am
Biogen
ALS
FDA
tofersen
FDA seems poised to approve a new drug for ALS, but does it work?
NPR
Wed, 09/21/22 - 10:12 am
Amylyx
AX0035
FDA
ALS
FDA, NIH initiative aims to speed development of drugs for ALS, other brain diseases
BioPharma Dive
Mon, 09/19/22 - 09:07 am
ALS
drug development
NIH
FDA
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »